Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | ACACB | O00763 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10243580 | 0.86 | ACACB (0.49) | NPC1RAB9ASMN1; SMN2ACACB | |
| SCHEMBL10243497 | 0.86 | SLC22A1 (0.43) | ALOX5SMN1; SMN2 | |
| SCHEMBL10244300 | 0.85 | MTNR1A (0.48) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL10244037 | 0.84 | CYP1A2 (0.46) | ALOX5NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL10244298 | 0.83 | TDP1 (0.42) | NPC1RAB9ASMN1; SMN2L3MBTL1MAPT | |
| SCHEMBL10244480 | 0.81 | CYP1A2 (0.43) | RAB9ASMN1; SMN2ACACB | |
| SCHEMBL10244079 | 0.81 | ALDH1A1 (0.40) | SMN1; SMN2L3MBTL1MAPT | |
| SCHEMBL10243510 | 0.80 | ALOX5 (0.40) | ALOX5SMN1; SMN2L3MBTL1 | |
| SCHEMBL10243697 | 0.80 | ALDH1A1 (0.43) | MAPT | |
| SCHEMBL10243433 | 0.79 | MAPT (0.43) | SMN1; SMN2L3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097708-B2 | 10a-Azalide compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-8097708-B2 | 10a-Azalide compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281292-A1 | 10a-Azalide Compound | IL17A, AZI2, HDAC9 | ALOX5 2387/4885NPC1 209/4885RAB9A 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.